Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

111, Inc. executive chairman Dr. YU Gang receives 2021 China Artificial Intelligence Award

Dr. YU Gang, co-founder and executive chairman of 111, Inc. (NASDAQ:YI), received the 2021 China AI Golden Goose Award for outstanding achievements. In accepting the award at the 2021 China Artificial Intelligence...

October 19, 2021

Developments

Entasis posts positive topline Phase 3 results with SUR-DUR

Entasis Therapeutics (NASDAQ:ETTX) announced positive topline results from its ATTACK global Phase 3 trial evaluating the safety and efficacy of SUL-DUR (sulbactam-durlobactam) versus colistin in patients with...

October 19, 2021

Developments

111, Inc. selected to 2021 China Top 20 Internet Healthcare Companies list

111, Inc. (NASDAQ:YI) was selected as one of the 2021 Top 20 Internet Healthcare Enterprises in China for its innovation and promotion in the internet+healthcare field and its transformative platform serving the...

October 15, 2021

Developments

VistaGen expands PH948 in Phase 2a trial for adjustment disorder

VistaGen Therapeutics (NASDAQ:VTGN) initiated a Phase 2a clinical trial to evaluate the efficacy, safety and tolerability of PH94B as a potential treatment of anxiety in adults with adjustment disorder with anxiety...

October 14, 2021

Developments

FDA accepts Altamira 510(k) application for Bentrio

Altamira Therapeutics’ (NASDAQ:CYTO) 510(k) application for premarket clearance for its Bentrio nasal spray for protection against airborne allergens was accepted for review by the FDA. The application now moves to a...

October 14, 2021

Developments

Labster to acquire UbiSim in virtual reality training expansion

Labster, a leading platform for virtual labs and interactive science based in Denmark, signed a definitive agreement to acquire UbiSim, a virtual reality training platform for nursing, in a move to further transform...

October 14, 2021

Developments

IntelGenx to resume Phase 2a patient screening with Montelukast VersaFilm in AD

IntelGenx (TSX:IGX; OTCQB:IGXT) intends to resume patient screening in the ongoing Montelukast VersaFilm Phase 2a BUENA clinical trial in patients with mild-to-moderate Alzheimer’s disease (AD) following Health Canada’s...

October 12, 2021

Developments

Titan Pharma, MUSC Foundation in research, option license agreement

Titan Pharmaceuticals (NASDAQ:TTNP) entered into a research and option license agreement with the MUSC Foundation for Research Development (MUSC FRD) and will conduct certain research, evaluation, proof-of-concept...

October 12, 2021

Developments

Supernus Pharma to acquire Adamas Pharma for $400-million plus CVRs

Supernus Pharmaceuticals (NASDAQ:SUPN) agreed to acquire Adamas Pharmaceuticals (NASDAQ:ADMS) in a tender offer for $8.10 a share in cash, or about $400-million plus two non-tradable contingent value rights (CVR). The...

October 11, 2021

Developments

Hirosaki University Hospital to initiate Asensus Senhance Robotic Surgery program

Hirosaki University Hospital agreed to lease and utilize a Senhance Surgical System from Asensus Surgical (NYSE American: ASXC), which is digitizing the interface between surgeon and patient to enhance performance...

October 6, 2021

Developments

IntelGenx cleared to graduate to Toronto Stock Exchange

IntelGenx Technologies (TSXV:IGX; OTCQB:IGXT) received final approval to graduate to the Toronto Stock Exchange from the TSX Venture Exchange. The company’s common stock; 8% convertible debentures, with a maturity date...

October 5, 2021

Developments

VistaGen reports new mechanism of action data for PH94B

VistaGen Therapeutics (NASDAQ:VTGN) announced new mechanism of action data from a preclinical tissue distribution study in laboratory rats demonstrating that a single intranasal administration of radiolabeled carbon-14...

October 5, 2021

Developments

Lanier Biotherapeutics in license pact with Alloy Therapeutics

Newly formed antibody developer Lanier Biotherapeutics entered into a license agreement with Alloy Therapeutics, a closely held drug discovery company. Under the accord, Alloy will acquire the AbeoMouse and Direct...

October 5, 2021

Developments

IntelGenx, Aquestive in pact with men’s health company for Tadalafil oral films in U.S.

IntelGenx (TSXV:IGX; OTCQB:IGXT) and Aquestive Therapeutics (NASDAQ:AQST), its co-development and commercialization partner for Tadalafil oral films for the treatment of erectile dysfunction (ED) and benign prostatic...

September 30, 2021

Developments

FDA clears TransMedics transplant OCS Liver System

TransMedics Group (NASDAQ:TMDX) received premarket approval from the FDA of its OCS Liver System for use with organs from donors after brain and circulatory death. “We are extremely proud of this approval of our...

September 29, 2021

Developments

Hepion Pharma drug-drug-interaction study with CRV431 meets all endpoints

Hepion Pharmaceuticals (NASDAQ:HEPA) met all endpoints in a drug-drug-interaction study with its lead drug candidate, CRV431. The randomized, open label study was conducted in 24 healthy volunteers to determine if...

September 29, 2021

Developments

Altamira Therapeutics files Bentrio 510(k) for allergy indication

Altamira Therapeutics’ (NASDAQ:CYTO) Bentrio is an OTC nasal spray that is drug- and preservative-free and designed to provide triple protection against airborne viruses and allergens. First, it helps to protect the...

September 27, 2021

Developments

Tryp Therapeutics files IND for Phase 2a eating disorders study

Tryp Therapeutics (CSE TRYP; OTCQB:TRYPF) submitted an IND with the FDA to evaluate its clinical candidate, TRP-8802, in a Phase 2a study for the treatment of patients with eating disorders. The trial is being conducted...

September 23, 2021

Developments

Cognetivity Neurosciences to place ICA system in Dubai

Cognetivity Neurosciences (CSE:CGN; OTCQB:CGNSF; FWB:1UB) reached its first commercial agreement for the Integrated Cognitive Assessment (ICA) to be deployed at the Clemenceau Medical Center (CMC) in Dubai. CMC is...

September 22, 2021

Developments

Profound Medical gets recommendation from Timelo Investment

During a BNN Bloomberg TV interview, Jean-Francois Tardif, founder and portfolio manager of Timelo Investment Management, praised the prospects of Profound Medical (NASDAQ:PROF; TSX:PRN). “Profound has an FDA-approved...

September 20, 2021

Developments

Health Canada clears first-in-man study of OpSens guidewire

OpSens (TSX:OPS; OTCQX:OPSSF) received Health Canada’s approval to begin a first in-man study with its SavvyWire, a guidewire developed specifically for transcatheter aortic valve replacement (TAVR). ...

September 20, 2021

Developments

Heritage Cannabis launches first Opticann CB4 medical products in Canada

Heritage Cannabis (CSE:CANN; OTCQX:HERTF) announced that Opticann, the medical brand and subsidiary of Heritage, is launching its first suite of CB4 branded products and has launched Opticann.ca in Canada...

September 20, 2021

Subscribe